- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
Vol. 3, No. 3
Fall 2013
The Fall 2013 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
Relevant court decisions highlighted in this issue:
- Sunovion Pharma., Inc. v. Teva Pharms. USA, Inc. (Fed. Cir. Sept. 26, 2013)
- Pronova Biopharma Norge v. Teva Pharma. USA, Inc. (Fed. Cir. Sept. 12, 2013)
- Teva Pharma. USA, Inc. v. Sandoz, Inc. (Fed. Cir. July 26, 2013)
Read more about these and other important court decisions, New ANDA Cases, ANDA Litigation Settlements, ANDA Approvals, and Generic Launches.
Related Professionals
"Egregious” misconduct on the part of the inventor—someone who is well versed in pharmaceutical formulations and the patent prosecution and enforcement processes—resulted in the Court’s finding of inequitable conduct, laches, and disclaimer.
After construing certain disputed claim terms, the court found the asserted claims infringed and not invalid.
Plaintiffs’ claim construction was adopted because defendants’ proposed construction attempted to read a limitation into the claim and defendants could not prove that a construction in a related case had preclusive effect; as a result, court granted summary judgment of infringement.
Reference Listed Drug, NDA Holder, Generic Drug Name, ANDA Applicant(s), Indication and Launch Date
Defendants failed to meet their burden in showing that the asserted claims were invalid for not meeting the written description requirement and non-enablement.
Because all of defendant’s activity fell under the safe harbor provision, it could not constitute patent infringement.
Based on its claim construction, the court denied defendant’s motion for summary judgment of non-infringement, and because the prior art failed to address the food effect that was the central innovation of the patent-in-suit, summary judgment of invalidity was denied.
Shipping samples that are covered by the patent-in-suit without a confidentiality agreement, without a limitation on usage, and to a skilled artisan that is able to ascertain the claimed elements, is a public use under § 102(b).
An action by the FDA during the pendency of the instant actions rendered claims of infringement and the counterclaims asserting non-infringement moot, and the court declined to exercise jurisdiction over counterclaims asserting invalidity.
Finding that defendants infringe claims 6, 12-16 and that claims 6, 12-16 of the patent-in-suit are invalid for obviousness.
Reversing district court decision of summary judgment of non-infringement and granting infringement as a matter of law.
Granting motion to dismiss because Defendants’ acts were protected by the safe harbor provision of §271(e)(1)
The term “molecular weight” is indefinite because the claims do not indicate which average molecular weight measure is intended, and two different methods were relied on during prosecution to argue against/avoid rejection.)
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.